Re: Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.

摘要

Background: In patients with metastatic renal cell carcinoma (mRCC), the timing of systemic targeted therapy in relation to cytoreductive nephrectomy (CN) is under investigation. Objective: To evaluate postoperative complications after the use of presurgical targeted therapy prior to CN. Design, Setting, and Participants: A retrospective review of all patients who underwent a CN at The University of Texas M.D. Anderson Cancer Center from 2004 to 2010 was performed. Inclusion in this study required documented evidence of mRCC, with treatment incorporating CN. Interventions: Patients receiving presurgical systemic targeted therapy prior to CN were compared to those undergoing immediate CN. Measurements: Complications were assessed using the modified Clavien system for a period of 12 mo postoperatively.